Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

Kidney Cancer Research Bureau51 enrolled

Overview

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Metastatic Renal Cell Carcinoma

Interventions

CapecitabineDRUG

1,250 mg/m2 orally twice a day, days 1-14

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically confirmed non-clear cell renal cell carcinoma * confirmed metastatic sites * no chemotherapy in history Exclusion Criteria: * metastases in CNS * previous targeted therapy * other tumor

Locations (1)

Natalia Petenko

Moscow, Russia

Outcomes

Primary Outcomes

Overall response rate

Time frame: 12 months

Secondary Outcomes

Overall survival Progression-free survival

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.